Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onsetGLAmutation c.936+919G>A (IVS4+919G>A)
Top Cited Papers
- 26 June 2009
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (10), 1397-1405
- https://doi.org/10.1002/humu.21074
Abstract
Fabry disease (α‐galactosidase A (α‐Gal A, GLA) deficiency) is a panethnic inborn error of glycosphingolipid metabolism. Because optimal therapeutic outcomes depend on early intervention, a pilot program was designed to assess newborn screening for this disease in 171,977 consecutive Taiwanese newborns by measuring their dry blood spot (DBS) α‐Gal A activities and β‐galactosidase/α‐Gal A ratios. Of the 90,288 male screenees, 638 (0.7%) had DBS α‐Gal A activity 10. A second DBS assay reduced these to 91 (0.1%). Of these, 11 (including twins) had 30% (Group‐C) of mean normal leukocyte α‐Gal A activity. All 11 Group‐A, 61 Group‐B, and 1 Group‐C males had GLA gene mutations. Surprisingly, 86% had the later‐onset cryptic splice mutation c.936+919G>A (also called IVS4+919G>A). In contrast, screening 81,689 females detected two heterozygotes. The novel mutations were expressed in vitro, predicting their classical or later‐onset phenotypes. Newborn screening identified a surprisingly high frequency of Taiwanese males with Fabry disease (∼1 in 1,250), 86% having the IVS4+919G>A mutation previously found in later‐onset cardiac phenotype patients. Further studies of the IVS4 later‐onset phenotype will determine its natural history and optimal timing for therapeutic intervention. Hum Mutat 30:1–9, 2009.This publication has 31 references indexed in Scilit:
- Agalsidase-Beta Therapy for Advanced Fabry DiseaseAnnals of Internal Medicine, 2007
- Fabry disease: Guidelines for the evaluation and management of multi-organ system involvementGenetics in Medicine, 2006
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*American Journal of Human Genetics, 2006
- Disease manifestations and X inactivation in heterozygous females with Fabry diseaseActa Paediatrica, 2006
- Fabry disease: Identification of 50 novel α-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutationsHuman Genomics, 2006
- Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective studyThe Lancet, 2005
- dentification of Fabry’s disease by the screening of a-galactosidase A activity in male and female hemodialysis patientsClinical Nephrology, 2005
- Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak populationJournal of Molecular Medicine, 2005
- Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac PhenotypeAmerican Journal of Human Genetics, 2002
- Fabry disease: enzymatic diagnosis in dried blood spots on filter paperClinica Chimica Acta; International Journal of Clinical Chemistry, 2001